As the PNH Market Co
As the PNH Market Continues to Crowd, Spherix Announces New Suite of Advisory Services to Explore Continued Unmet Needs and Track New Launches
26 juin 2024 04h00 HE | Spherix Global Insights
EXTON, PA, June 26, 2024 (GLOBE NEWSWIRE) -- Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired disorder in which red blood cells prematurely break apart, a process known as hemolysis....
Novartis' Fabhalta S
Novartis' Fabhalta Shows Promise in Addressing Critical Gaps in C3 Glomerulopathy Treatment
13 juin 2024 11h39 HE | Spherix Global Insights
EXTON, PA, June 13, 2024 (GLOBE NEWSWIRE) -- Complement 3 glomerulopathy (C3G) is a rare kidney disease that presents significant challenges for both patients and nephrologists. Currently, there are...
Lynch Carpenter Logo-01.png
Lynch Carpenter Investigates Claims in Cencora, Inc. Data Breach
29 mai 2024 13h46 HE | Lynch Carpenter
PITTSBURGH, May 29, 2024 (GLOBE NEWSWIRE) -- Cencora, Inc. recently announced that it suffered from a cybersecurity attack that occurred in February of 2024, which impacted the personal information...
Novartis’ Intravenou
Novartis’ Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthritis Treatment, While Pending Launch of UCB’s Bimzelx Poised to Further Disrupt the Market
16 avr. 2024 14h06 HE | Spherix Global Insights
EXTON, PA, April 16, 2024 (GLOBE NEWSWIRE) -- In October of 2023, the US FDA approved Novartis’ intravenous (IV) formulation of Cosentyx (secukinumab) for the treatment of psoriatic arthritis (PsA),...
IgA Nephropathy Pipe
IgA Nephropathy Pipeline Dynamics Signal Further Treatment Evolution on the Horizon
14 mars 2024 15h11 HE | Spherix Global Insights
EXTON, PA, March 14, 2024 (GLOBE NEWSWIRE) -- The past several years have brought a transformative shift to the IgA nephropathy (IgAN) treatment landscape, including the introduction of two new...
Novartis' Cosentyx S
Novartis' Cosentyx Shows Promising Early Progress in Treating Hidradenitis Suppurativa, Poised for Significant Future Adoption at the Expense of AbbVie's Humira
10 janv. 2024 15h58 HE | Spherix Global Insights
Exton, Pennsylvania, Jan. 10, 2024 (GLOBE NEWSWIRE) -- In late October 2023, the FDA granted approval to Novartis' Cosentyx (secukinumab) for treating hidradenitis suppurativa (HS), marking it as...
logo.png
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide
21 déc. 2023 07h30 HE | Arch Biopartners
TORONTO, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it received approval in Turkey from the Kocaeli...
Related Sciences - Press Logo.png
Related Sciences Adds 8 New Senior Advisors Including Former CEOs and Heads of R&D from Genentech, Novartis, Seagen, Pfizer, Celgene, and AstraZeneca
19 déc. 2023 10h00 HE | Related Sciences
Former CEOs and executives from Genentech, Novartis, Seagen, Pfizer, and Celgene join drug AI/ML drug discovery firm Related Sciences as senior advisors.
US Neurologists Emph
US Neurologists Emphasize Tremendous Unmet Treatment Need in Parkinson's Disease, According to Spherix Global Insights
07 nov. 2023 10h41 HE | Spherix Global Insights
Exton, Pennsylvania, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Parkinson's disease (PD) is the second-most prevalent neurodegenerative disorder following Alzheimer's disease, affecting an estimated one...
Matthew Perry headshot
Fairway Consulting Group Appoints Matthew Perry as Vice President of Executive Search
19 oct. 2023 08h45 HE | Fairway Consulting Group
Fairway Consulting Group Appoints Matthew Perry as Vice President of Executive Search